Population pharmacokinetic—pharmacodynamic modeling of ketamine‐induced pain relief of chronic pain

Aims: Pharmacological treatment of chronic (neuropathic) pain is often disappointing. In order to enhance our insight in the complex interaction between analgesic drug and chronic pain relief, we performed a pharmacokinetic—pharmacodynamic (PK—PD) modeling study on the effect of S(+)‐ketamine on pain scores in Complex Regional Pain Syndrome type 1 (CRPS‐1) patients.

[1]  A. Gorman,et al.  Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine , 1999, Pain.

[2]  B. Chizh.  Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways , 2007, Journal of psychopharmacology.

[3]  N. Holford,et al.  Modeling the norketamine metabolite in children and the implications for analgesia , 2007, Paediatric anaesthesia.

[4]  R. Harden,et al.  External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria , 1999, Pain.

[5]  清河 あゆみ,et al.  Complex regional pain syndrome type 1 , 2020, Definitions.

[6]  E. Bruera,et al.  Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene , 2007, PAIN.

[7]  Jörn Lötsch,et al.  Genetic modulation of the pharmacological treatment of pain. , 2009, Pharmacology & therapeutics.

[8]  F. Benedetti,et al.  Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems , 1999, The Journal of Neuroscience.

[9]  I. Kissin.  The Development of New Analgesics Over the Past 50 Years: A Lack of Real Breakthrough Drugs , 2010, Anesthesia and analgesia.

[10]  F. M. Borgbjerg,et al.  Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. , 1997, European journal of pharmacology.

[11]  N. Holford,et al.  Investigating the pharmacodynamics of ketamine in children , 2007, Paediatric anaesthesia.

[12]  H. Handwerker.  About the European Journal of Pain , 2012, European journal of pain.

[13]  J. Dieleman,et al.  The incidence of complex regional pain syndrome: A population-based study , 2007, Pain.

[14]  A. M. Harvey.  Classification of Chronic Pain—Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms , 1995 .

[15]  H. Merskey,et al.  Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. , 1994, Pain. Supplement.

[16]  A. Dahan,et al.  The Involvement of the &mgr;-Opioid Receptor in Ketamine-Induced Respiratory Depression and Antinociception , 2001, Anesthesia and analgesia.

[17]  J. Mogil.  Animal models of pain: progress and challenges , 2009, Nature Reviews Neuroscience.

[18]  D. Borsook.  Ketamine and chronic pain – Going the distance , 2009, PAIN.

[19]  B. Ploeger,et al.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. , 2008, Trends in pharmacological sciences.

[20]  Y. Hijazi,et al.  Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[21]  J. Marinus,et al.  Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1 , 2009, PAIN.

[22]  R. Dubner,et al.  Placebo and naloxone can alter post-surgical pain by separate mechanisms , 1983, Nature.

[23]  T. Baillie,et al.  Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. , 1986, Journal of medicinal chemistry.

[24]  J. Field.  Complex Regional Pain Syndrome: a review , 2013, The Journal of hand surgery, European volume.

[25]  P. Veldman,et al.  Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients , 1993, The Lancet.

[26]  A. Verbeek,et al.  [Complex regional pain syndrome type 1? In 77% of people had a different diagnosis]. , 2009, Nederlandsch tijdschrift voor geneeskunde.

[27]  Steven L. Shafer,et al.  Measuring the predictive performance of computer-controlled infusion pumps , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  Paul F. White,et al.  Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  Lennart Ljung,et al.  System Identification: Theory for the User , 1987 .

[30]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[31]  O. Guttmann,et al.  Images in clinical medicine. Complex regional pain syndrome type 1. , 2008, The New England journal of medicine.

[32]  A. Dahan,et al.  S(+)-ketamine Effect on Experimental Pain and Cardiac Output: A Population Pharmacokinetic-Pharmacodynamic Modeling Study in Healthy Volunteers , 2009, Anesthesiology.

[33]  R. Schwartzman.  New treatments for reflex sympathetic dystrophy. , 2000, The New England journal of medicine.